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Objective: Selective serotonin reuptake inhibitors (SSRIs) have increased cognitive performance in 
some clinical studies of Alzheimer’s disease (AD), but it is has been difﬁ  cult to dissociate whether 
this is due to direct effects on cognition (neurochemical or disease-modifying) or a secondary effect 
of mood stabilization. We performed a systematic review for preclinical and human clinical trial 
evidence to support the use of SSRIs speciﬁ  cally for the management of cognitive decline in AD.
Data sources: (1) PUBMED without language restrictions from 1950s until 2004 and 
updated August 2006, terms: “serotonin uptake inhibitors”[MeSH] AND (“Alzheimer 
disease”[MeSH] OR “Cognition Disorders”[MeSH]) NOT “Parkinson disease”[MeSH] AND 
(Clinical Trial[ptyp] OR Letter[ptyp] OR Meta-Analysis[ptyp] OR Randomized Controlled 
Trial[ptyp]) AND “alzheimer disease” [MESH] OR “Alzheimer*” combined with AND to 
“ssri*” OR “serotonin reuptake inhibitors” [MESH] NOT Review[ptyp]. (2) Cochrane Database 
of Systematic Reviews, keywords “SSRI” and “Alzheimer’s”.
Study selection: The PubMed search yielded 57 hits. Of these, 23 were included in this review 
for their speciﬁ  city to SSRI use in AD or indications on efﬁ  cacy beyond depressive symptoms. 
The other 34 citations were excluded because: (1) depression or other mood or behavioral dis-
turbance severity was the reported outcome measure, (2) effects of SSRIs on cognition were 
confounded by concomitant use of other drugs, (3) subjects described were young adults, and/or 
(4) subjects had traumatic brain injury. The Cochrane Database of Systematic Reviews, 3rd 
Quarter 2006, yielded six citations related to SSRIs.
Data extraction: Data extracted from clinical trials included name of SSRI tested, cognitive 
outcome measures, and adverse events reported, which could include cognitive worsening.
Data synthesis: Preclinical evidence for use of SSRIs to enhance cognition in AD includes an 
effect at the hippocampus through carbonic anhydrase activation or stimulation of hippocampal 
neurogenesis. The chemical structure of paroxetine, and not intrinsic SSRI activity, may also 
affect APP ectodomain expression to reduce amyloid plaque formation. Clinical trials in AD 
generally have not assessed cognitive outcomes independently from mood or behavior stabi-
lization. Currently, clinical studies in AD only indirectly support the use of SSRIs for disease 
modiﬁ  cation by conﬁ  rming a serotonergic deﬁ  cit during the course of illness.
Conclusions: Lack of supportive evidence for SSRIs as cognition enhancers or disease modi-
ﬁ  ers in AD is the result of omissions in clinical trial design, as opposed to reporting of negative 
outcomes. The preclinical evidence warrants the study of SSRIs in AD using mood, behavior, 
cognition, neurochemistry, and possibly neuroimaging as outcome variables.
Keywords: Alzheimer’s disease, Amyloid precursor protein, APP ectodomain, carbonic anhy-
drase, selective serotonergic reuptake inhibitor
Introduction
Short term memory loss with associated hippocampal pathology is typically the earliest 
feature of Alzheimer’s disease (AD). Not only do the hippocampi atrophy as patients Neuropsychiatric Disease and Treatment 2007:3(5) 628
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progress from mild cognitive impairment to AD (Jack et al 
2005), but AD pathology begins in entorhinal cortex and 
hippocampus (Braak and Braak 1991). The evidence thus 
far focuses prevention and treatment for AD on preservation 
of hippocampal structure and function.
The neurotransmitter serotonin (5HT) has recently 
been linked to AD pathology in part because serotonergic 
receptors densely populate the hippocampus. Furthermore, 
extracellular 5HT levels have been correlated with memory 
performance. Serotonin depletion impairs memory encod-
ing. (Schiapparelli et al 2005; Ueda et al 2005; van der 
Veen et al 2006; Khaliq et al 2006) The verbal memory 
impairment in former ecstasy (MDMA) users is believed to 
be the result of MDMA’s selective toxicity to serotonergic 
neurons.(Thomasius et al 2006) Cognitive improvement does 
not follow agonism across all 5HT receptor types (Meneses 
1998; Meneses 2001; Meneses 2003; Meneses and Hong 
1995; Meneses and Terron 2001; Meneses et al 1997). For 
example, 5HT6R blockade facilitates memory consolidation 
in rats. (Mitchell and Neumaier 2005)
Selective serotonin reuptake inhibitors (SSRIs) raise 
extracellular 5HT levels and have shown effects both on 
hippocampal plasticity and neurogenesis in animal models 
and treated patients. Hippocampal evoked potentials mani-
fest enhanced plasticity after administration of ﬂ  uvoxamine 
(Ohashi et al 2002) and ﬂ  uoxetine (Smith and Lakoski 1998; 
Stewart and Reid 2000). Escitalopram, however, decreases 
long term potentiation (LTP) in CA1 neurons of the dorsal 
hippocampus (Mnie-Filali et al 2006), highlighting poten-
tial differences among the SSRIs for hippocampal effects. 
Paroxetine has led to increased hippocampal volumes in 
patients treated for post-traumatic stress disorder (PTSD) 
(Bremner and Vermetten 2004), implying promotion of 
neurogenesis.
Although patients with PTSD whose hippocampal vol-
umes improved after treatment with paroxetine also showed 
improved memory performance (Bremner and Vermetten, 
2004), enhancement of neuronal plasticity seems inversely 
related to memory performance. Fluoxetine shows no effect 
on spatial learning in rats (Stewart and Reid 2000) and even 
decreases memory retention in rats pretreated with the cogni-
tive enhancing peptide, ghrelin (Carlini et al 2007). Similarly, 
despite escitalopram’s inhibitory effect on LTP, its less 
potent racemic form, citalopram, is reported to restore spatial 
memory to both rats and mice impaired by anticholinergic 
preparations (Egashira et al 2006). The discrepancy of results 
from these studies on SSRIs and memory performance may 
be related to differences in acute vs chronic use of SSRIs or 
administration of low vs high maintenance doses (Dumont 
et al 2005).
Most studies describe a less direct role for SSRIs in 
maintaining the hippocampus. SSRIs diminish factors that 
lead to apoptosis, such as stress-induced glucocorticoid 
levels (MacPherson et al 2005; Mattson et al 2004; Sapolsky 
2003).
Inverse relationships between 5HT and neuropeptides 
may also impact hippocampal function. Neurokinin-1 (NK-1) 
agonists have effects on the dorsal raphe that can lead to 
decreased 5HT release, which would impact negatively 
on memory-related activity in the hippocampus. However, 
relevant to the cholinergic hypothesis of AD, enhancement 
of cholinergic activity within the mouse hippocampus by 
substance P is dependent upon NK-1 receptors. It is not yet 
clear what the relative costs to the AD patient would be if 
manipulation of NK-1 receptors leads to the loss of cholin-
ergic facilitation vs. loss of serotonergic transmission (Gobbi 
and Blier 2005).
The impact of SSRIs on memory may stem from interac-
tions with other modulators of memory that act through brain-
derived neurotrophic factor (BDNF). Chronic ﬂ  uoxetine and 
sertraline administration enhances cAMP response element 
binding protein expression in hippocampus, and this leads 
to increased BDNF expression. (Nibuya et al 1996) Chronic 
use of SSRIs also stimulates norepinephrine release, likely 
due to effects at the locus ceruleus (Page and Abercrombie 
1997; Thomas et al 1998; Vizi et al 2004; Hajos-Korcsok 
et al 2000). The combination of increased extracellular 5HT 
and norepinephrine observed after administration of dulox-
etine but not ﬂ  uoxetine enhances BDNF mRNA expression 
(Calabrese et al 2007), but the impact of BDNF on memory 
appears not to be related to hippocampal function. Instead, 
this increase in BDNF is observed in frontal lobes and not 
the hippocampus (Calabrese et al 2007). Improvements in 
memory performance are possible, if the frontal systems for 
sustained attention are facilitated.
Memory loss and hippocampal atrophy also can occur 
in depression (Sheline et al 1999; Burt et al 1995). Sheline 
et al (2002) reported preliminary data indicating an associa-
tion among depression, memory loss, hippocampal atrophy, 
and decreased 5HT receptor binding. This has been modeled 
by Meeter et al (Meeter et al 2006). Clinicians commonly 
prescribe SSRIs to patients with AD, intending relief of sec-
ondary depression, anxiety, and agitation (Pollock et al 1999; 
Bains et al 2005; Nyth and Gottfries 1990). This raises a 
challenge in interpreting the results of both animal and human 
studies: does administering an SSRI prior to training enhance Neuropsychiatric Disease and Treatment 2007:3(5) 629
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learning by decreasing the subject’s anxiety or depressive 
symptoms during testing? This illustrates the difﬁ  culty of 
distinguishing cognitive effects from behavioral or emotional 
ones and will be discussed in the review.
Whether as a symptomatic or disease-modifying interven-
tion for AD, use of SSRIs is supported by autopsy data. Patients 
with AD compared against age-matched controls have seroto-
nergic deﬁ  cits manifested by degeneration of the raphé nuclei 
and decreased 5HT and metabolite 5-hydroxy-indole acetic acid 
(5-HIAA) levels in brain parenchyma and the cerebrospinal 
ﬂ  uid (CSF) (Chen et al 1996; Bowen et al 1988; Procter et al 
1992; Nazarali and Reynolds 1992; Chen et al 2000; Sjogren 
et al 1998; Reinikainen et al 1988). CSF 5-HIAA levels are low 
during the AD patient’s life as well (Blennow et al 1992), with 
differences between early and late onset AD. 5-HIAA correlates 
positively with cognitive impairment in early onset AD but with 
motor impairment in late onset AD (Brane et al 1989).
We reviewed the preclinical and clinical evidence for 
beneﬁ  ts of SSRIs to cognition or to disease modiﬁ  cation in 
AD. We report a systematic literature search for efﬁ  cacy of 
SSRIs in AD outside of treatment for secondary depressive 
and anxious symptoms.
Methods
PUBMED was searched without language restrictions 
from the 1950s to 2004 and updated August 2006. Due to 
changes in the PubMed database, two different search strate-
gies have been used. Initially the search was as follows: 
“serotonin uptake inhibitors”[MeSH] AND (“Alzheimer 
disease”[MeSH] OR “Cognition Disorders”[MeSH]) 
NOT “Parkinson disease”[MeSH] AND (Clinical 
Trial[ptyp] OR Letter[ptyp] OR Meta-Analysis[ptyp] 
OR Randomized Controlled Trial[ptyp]). Using specific 
drug names (eg, fluoxetine) instead of “Serotonin Uptake 
Inhibitors” did not add to the yield. The following two 
search statements were added at the update: “alzheimer 
disease” [MESH] OR “Alzheimer*” combined with AND 
to “ssri*” OR “serotonin reuptake inhibitors” [MESH] 
NOT Review[ptyp].
There is no MeSH term for “disease modification” 
or “neurodegeneration,” but we did conduct a search 
using “Hippocampus” [MeSH] AND “serotonin/
pharmacology”[MeSH] AND “Alzheimer disease/drug 
therapy” [MeSH].
To cross-check for any further citations missed in our 
search strategy, we also checked references identiﬁ  ed by 
reports from the Cochrane Database of Systematic Reviews 
using keywords “SSRI” and “Alzheimer’s,” which were 
more inclusive search terms than permutations of “serotonin 
reuptake inhibitor” and “Alzheimer’s disease” with either 
of the preceding keywords. It is possible that our search 
strategy omitted pertinent references from this review, but 
we believe we cast the widest and most reasonable net to 
ﬁ  nd relevant papers.
The PubMed search yielded 57 hits. Of these, 23 were 
included in this review for their speciﬁ  city to SSRI use in AD 
and indications on efﬁ  cacy beyond depressive symptoms. The 
other 34 citations were excluded because: (1) depression or 
other neuropsychiatric symptom severity was the outcome 
measure, (2) effects of SSRIs on cognition were confounded 
by concomitant use of other drugs, (3) subjects described 
were young adults, and/or (4) subjects had traumatic brain 
injury. We did not actively search for adverse events in AD 
patients taking SSRIs but summarized relevant ﬁ  ndings from 
papers that appeared within our search.
The search for MeSH terms “Hippocampus” AND 
“serotonin/pharmacology” AND “Alzheimer disease/drug 
therapy” revealed one citation (Schechter et al 2005) that 
supported a role for serotonin in hippocampal function but 
did not refer speciﬁ  cally to SSRIs.
The Cochrane Database of Systematic Reviews, 3rd 
Quarter 2006, yielded six citations related to SSRIs. Three 
of these citations referred to treatment of depression. The 
remaining three citations referred to relevant papers; one 
citation was added to the review, and the other two had been 
identiﬁ  ed previously by our search strategy.
We have organized our review to present in vitro and 
animal experiments as Preclinical Evidence, followed by 
evidence from human clinical trials to support ﬁ  rst cognition-
enhancing, then disease modifying effects of the SSRIs.
Cognition-enhancing properties 
of SSRIs
Preclinical evidence for use of SSRIs 
to enhance cognition in AD
Aside from effects on 5HT receptors, SSRIs may have an 
effect at the hippocampus by acting as carbonic anhydrase 
activators (Sun and Alkon 2001). This hypothesis merits 
discussion because separate experiments indicate a mecha-
nism of action beneﬁ  cial to hippocampal function, but this 
effect has yet to be demonstrated in a clinical trial. Carbonic 
anhydrase catalyzes the production of bicarbonate (HCO3) 
from carbon dioxide and water. This in turn can increase the 
proportion of GABAergic interneurons triggering excitatory 
responses in rat hippocampal pyramidal cells. SSRIs would Neuropsychiatric Disease and Treatment 2007:3(5) 630
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therefore incite GABAergic interneurons in a way that 
enhances synaptic efﬁ  cacy, spatial learning, and memory 
(Sun and Alkon 2001). Although spatial learning and memory 
performance improved in a rat using another carbonic anhy-
drase activator (Sun and Alkon 2001), we are not able to 
extrapolate from this study what continuous administration 
of an SSRI might do for the carbonic anhydrase hypothesis 
in elderly patients with AD. Casini et al showed a more direct 
connection between SSRIs and carbonic anhydrase with 
an in vitro experiment, in which the action of SSRIs upon 
carbonic anhydrase was blocked with acetazolamide (Casini 
et al 2003). The authors identify ﬂ  uoxetine, sertraline, and 
citalopram as carbonic anhydrase isozyme I and II activators, 
but they are less ambitious about cognitive effects on patients 
with AD than Sun and Alkon (2001). By contrast, Casini 
et al (2003) suggest that the carbonic anhydrase mechanism 
explains the antidepressant efﬁ  cacy of SSRIs in AD.
As above, some SSRIs may stimulate hippocampal 
neurogenesis (Bremner and Vermetten 2004; MacPherson 
et al 2005; Mattson et al 2004; Sapolsky 2003); which might 
then translate to cognitive enhancement, as well as disease 
modiﬁ  cation. We review studies in this area in the “Disease 
Modiﬁ  cation Properties” section below.
The hypotheses carried forward in preclinical trials give 
a rationale to expect SSRIs to have cognitive beneﬁ  ts in AD. 
However, clinical trials have not been designed to follow the 
preclinical results above. This is probably because most of the 
evidence supporting cognition-enhancing effects of SSRIs 
was reported well after the publication of Phase II clinical 
trials of SSRIs in patients with AD. As will be discussed 
in the next section, clinical trials of SSRIs have focused 
primarily on mood or behavioral effects and have not rigor-
ously tested memory or learning, measures of hippocampal 
neuronal activity, or changes in hippocampal volume as 
outcome measures.
Clinical evidence of SSRIs as cognitive 
enhancers
Although cognitive beneﬁ  ts are rarely central aims, they have 
been observed in several studies. Cutler et al enrolled four 
non-depressed patients with AD in a double-blind crossover 
study of serotonin reuptake blocker zimeldine and found that 
although there were drug responsive alterations in central and 
peripheral serotonergic function, they were unaccompanied 
by measurable changes in memory and/or reaction time 
(Cutler et al 1985). Taragano et al (1997) reported improve-
ment in MMSE scores among depressed patients with AD 
who were treated with SSRI ﬂ  uoxetine but attributed this 
improvement to the lifting of the depressive symptoms. 
In what may be the last clinical trial for subjects with AD 
excluding concomitant cholinesterase inhibitor therapy, the 
Depression in Alzheimer’s Disease Study (DIADS) clinical 
trial did not show differences on the MMSE for sertraline 
vs. placebo (Lyketsos et al 2003). A similar 16-week 
monotherapy trial of citalopram in early- and late-onset AD 
patients showed no improvement on the cognitive portions 
of the Gottfries-Brane-Steen geriatric rating scale (GBS) 
(Nyth and Gottfries 1990).
Munro et al (2004) found mixed SSRI effects on cogni-
tion when they split the DIADS data into gender groups: 
women with AD taking sertraline showed improvement on 
verbal learning and block design tasks compared to those 
on placebo; men worsened on these measures when taking 
sertraline. Lanctot et al (2002) report a greater prolactin 
release response to the non-selective 5HT reuptake inhibitor 
fenﬂ  uramine among women with higher Neuropsychiatric 
Inventory and BEHAVE-AD aggression scores and low 
MMSE scores at baseline. This may lend further support to 
gender differences in a beneﬁ  cial role for SSRIs in AD, but 
there were no cognitive outcome measures for this fenﬂ  ura-
mine challenge study.
Like Taragano, Mintzer (2003) concludes that cognitive 
beneﬁ  ts of SSRIs, if there are any, are likely to be secondary 
to their effect on mood or behavioral disturbances. This view 
is supported in a clinical drug trial by Pollock et al (2002). 
Patients with dementia (not necessarily due to AD) but not 
depression were admitted to the hospital for acute onset of 
severe agitation and treated with (1) the SSRI citalopram, 
(2) the neuroleptic perphenazine, or (3) placebo. One of the 
secondary outcome measures of the study was a cognitive 
subscale of the Neurobehavior Rating Scale. Patients in the 
citalopram arm of the study, in contrast to those randomized 
to perphenazine or placebo, showed signiﬁ  cant improvement 
on the cognitive subscale. The number needed to treat (NNT) 
to achieve either a partial or full response to citalopram in 
Pollock’s study was 3; for a full response the NNT was 
6. By comparison, the perphenazine NNT was 17 (Bruce 
Pollock, personal communication, February 17, 2005). Of 
note, the NNT for cholinesterase inhibitors to achieve a 
cognitive response in AD is 10 (Lanctot et al 2003). The 
NNT is impressive when compared to the widely used 
cholinesterase inhibitors, which are arguably the standard 
of care for AD (Courtney et al 2004). Although cognitive 
outcomes have been reported in a small number of studies, 
neither the cognitive subscales of the Neurobehavior Rating 
Scale nor the GBS nor the MMSE is a rigorous measure of Neuropsychiatric Disease and Treatment 2007:3(5) 631
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memory nor learning at the standard of the Wechsler Memory 
Scale-Revised Logical I and II (Wechsler 1987) or California 
Verbal Learning Test (Delis et al 1987).
Other than the negative study on a very small sample by 
Cutler et al (1985), no clinical trial has distinguished SSRI 
cognitive beneﬁ  ts from mood or behavioral stabilization. 
Even if one were to separate cognition-enhancement from 
behavior control, Predictive value of the rodent improve-
ments reported in preclinical trials has yet to be adequately 
assessed in clinical trials.
The only adverse cognitive events reported in AD 
have been “decreased concentration” in no more than six 
of 98 subjects taking citalopram in the Nyth and Gott-
fries study (1990). Case reports describe an 87 year old 
woman and four members of a separate family whose 
memory impairment began with ﬂ  uoxetine administration 
for depression and reversed after withdrawal of the drug. 
(Joss et al 2003, Huang et al 2004) There are insufﬁ  cient 
neuropsychological testing data from any of these reports 
to indicate common features of the cognitive worsening, eg, 
attentional vs encoding impairment.
SSRIs are frequently used concomitantly with cholines-
terase inhibitors in patients with AD (Pollock et al 1999). 
The positive study cited above allowed subjects to take 
acetylcholinesterase inhibitors (AChE-Is) concurrently, so 
long as they were on stable doses for a month prior to study 
enrolment (Pollock et al 2002); this amounted to approxi-
mately 30% of the sample. Finkel et al reported no speciﬁ  c 
cognitive improvements on the MMSE or ADAS-Cog when 
augmenting donepezil with sertraline in a double-blind study, 
although there were modest improvements on the Clinician’s 
Global Impression scale for the augmented group (Finkel 
et al 2004).
Tacrine, the ﬁ  rst cholinesterase inhibitor approved by 
the FDA for treatment of AD, has been shown to have 
non-competitive 5HT reuptake inhibition properties (Jos-
san et al 1992). McKenna et al (1997), following up on 
this report, explored analogues of tacrine for inhibition of 
serotonin uptake. Although they identiﬁ  ed one compound as 
a relatively potent SSRI, follow-up clinical trial data are not 
available. Another group, noting the frequent concomitant 
use of SSRIs and AChE-Is, created a combination drug by 
combining ﬂ  uoxetine and rivastigmine (Kogen et al 2002). 
They hypothesized that, “the antidepressive effect of sero-
tonin transport inhibitors might reduce a demand on cholin-
ergic systems in the brain to ameliorate cognitive effects.” 
The drug was developed in 2002, but neither pre-clinical 
nor clinical trial data have been published. It is not clear 
whether SSRIs enhance AD patient function by enhancing 
cholinesterase inhibitor effects or vice versa. Meneses (2003) 
suggests that AChE-Is potentiate SSRIs when the SSRI is 
given at a sub-effective dose.
Two more studies identiﬁ  ed by our literature search were 
clinical trials of SSRIs in patients with AD, but their designs 
focused on showing a serotonergic deﬁ  cit. Neither of the stud-
ies replicated the typical delivery of an SSRI to an AD patient 
or monitored cognition or disease modiﬁ  cation as outcome 
measures (Tohgi et al 1995). Tohgi et al (1995) reported that 
patients with AD or subcortical ischemic vascular dementia 
have lower baseline CSF 5HT levels than age-matched con-
trols. After a challenge with citalopram, AD CSF total 5HT 
levels doubled but, nevertheless, remained lower than the 
control group baseline CSF. This result conﬁ  rms the post-
mortem evidence of 5HT deﬁ  cit, as well as suggesting a 5HT 
deﬁ  cit in living subjects with AD. However, the study had no 
mood or behavioral or cognitive outcome measures, and thus 
does not provide evidence of a clinical beneﬁ  t. Furthermore, 
the investigators administered a citalopram challenge of 20 
mg daily over a two-week period. Patients with AD may 
further adjust their CSF 5HT levels if the citalopram admin-
istration were prolonged; most patients are given SSRI trials 
for at least 6 weeks at a time. Also, this was not a controlled 
challenge study; control subjects received neither placebo 
nor citalopram.
In summary, positive studies supporting SSRIs as cogni-
tion enhancers have not been able to differentiate their results 
from effects on mood and behavioral control as a matter of 
study design. The one study (Cutler et al 1985) to assess 
cognitive effects of an SSRI in AD without depression had 
negative results, but the same study design has not been 
replicated with more commonly prescribed SSRIs. Existing 
studies in living AD patients indirectly support the use of 
SSRIs by conﬁ  rming a serotonergic deﬁ  cit during the course 
of illness and suggesting that patents with AD are particularly 
responsive to SSRIs.
Disease modiﬁ  cation properties 
of SSRIs in AD
Preclinical evidence
In addition to providing symptomatic relief through compensa-
tion for a 5HT deﬁ  cit in AD, SSRIs may also reduce amyloid 
plaque formation, which likely has a causative role in the 
development of the cognitive impairment in AD. The amyloid 
plaque is made up of Aβ 1–42 oligomers, which are formed after 
clipping of amyloid precursor protein by β-secretase and then Neuropsychiatric Disease and Treatment 2007:3(5) 632
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γ-secretase. The ectodomain portion of APP shunts more of the 
APP away from the γ-secretase pathway and thereby promotes 
the production of “benign” amyloid. Two papers showed posi-
tive effects on APP ectodomain expression after agonism at 
5HT2a and 5HT2c receptors: Nitsch et al (1996) demonstrated 
this in vitro, and the rodent model of Arjona et al (2002) shows 
increases in APP ectodomain levels in the CSF after intraperi-
toneal injections of the 5HTR agonists. The guinea pigs used 
for this experiment were young and not cognitively impaired 
specimens, and no cognitive or behavioral testing was included 
in the study design (Arjona et al 2002). In both of these studies, 
the effects of the 5HT2a or 5HT2c agonist were reversed with 
ritanserin, but it has not yet been established that administration 
of SSRIs will have similar effects in AD patients.
Morse et al (2003) and Payton et al (2004) have screened 
drugs for their ability to stimulate expression of the APP 
ectodomain. Six of 1200 drugs screened for interactions 
with the ectodomain suppressed the appropriate target: one 
such drug was paroxetine (Payton et al 2003). Although the 
screen included several SSRIs. Morse et al (2004) found 
that the effect of paroxetine on the APP ectodomain seems 
related to its secondary iron chelator properties, similar to 
dimercaptopropanol, the mercury chelator, identiﬁ  ed in 
the Payton drug search. Thus, APP ectodomain modula-
tion may not be a universal property of SSRIs. Tucker 
et al (2006) have since conﬁ  rmed the beneﬁ  cial effect of 
paroxetine on Aβ levels in an AD mouse model: adding 
paroxetine to the animal’s drinking water reduced cortical 
Aβ peptide levels.
Pakaski et al (2005) report an increase in APP secre-
tion resulting from in vitro treatment of rat basal forebrain 
neurons with a different SSRI, citalopram, but the beneﬁ  t of 
this result seems counterintuitive. Unlike the studies above, 
SSRI administration enhances secretion of entire APPs and 
does not speciﬁ  cally alter expression of the APP ectodomain 
segment.
When Palotas et al (2004) used lymphocytes in a cDNA 
microarray to screen for a link between SSRIs and AD, 
they found support for a different disease modiﬁ  cation role 
for citalopram. Lymphocytes from patients with AD have 
impaired Aβ processing (Palotas et al 2002; Etcheberrigaray 
and Bhagavan 1999; Eckert et al 1998). These lymphocytes 
show ionic and signal transduction alterations, increasing 
susceptibility to apoptosis via oxidation. Challenge with 
citalopram for 4 weeks led to enhanced mRNA expression 
of the genes to prevent apoptosis in lymphocytes from 
both AD and non-AD control subjects (Palotas et al 2004). 
Messenger RNA expression and not cell survival was the 
outcome variable for this experiment. It is not yet clear what 
predictive validity a treated lymphocyte population may 
have for the CNS in AD or its microglial system, but this 
may be one way in which SSRIs could contribute to disease 
modiﬁ  cation in AD.
Another potential disease-modifying effect of SSRIs 
is hippocampal neurogenesis. Hippocampal atrophy is a 
frequent ﬁ  nding on magnetic resonance imaging in AD, 
although not required for clinical diagnosis due to lack of 
speciﬁ  city for AD. Neuropathologists use ﬁ  ndings of neuritic 
plaques with amyloid cores and neuroﬁ  brillary tangles in 
the hippocampi of patients to diagnose AD (National Insti-
tute on Aging 1997). Agents that rejuvenate hippocampal 
neuronal activity or neurogenesis might enhance cognition 
and/or modify the AD process. Our literature search elicited 
one study on the effect of ﬂ  uoxetine on hippocampal injury 
through isolation stress in a transgenic mouse model for AD 
(Dong et al 2004). The authors found that ﬂ  uoxetine reversed 
the negative effects of isolation stress on hippocampal cell 
proliferation and normalized the performance on a memory 
task. Malberg (2000) had previously reported that chronic 
treatment with antidepressants facilitates hippocampal neu-
rogenesis in rats. The effect was not speciﬁ  c to SSRIs: rats 
treated with the SSRI ﬂ  uoxetine or an MAO-inhibitor or a 
norepinephrine uptake inhibitor had similarly increased hip-
pocampal neuronal counts.
One study reporting apoptosis caused by an SSRI coun-
ters their potential beneﬁ  t for AD. Neurotrophic cytokine 
S100B enhances neuronal survival in vitro (Reeves et al 
1994). Administration of ﬂ  uoxetine to the young adult rat 
increases hippocampal levels of S100B (Haring et al 1993), 
but aging humans have increased levels of S100B mRNA 
expression (Sheng et al 1996), and excessive amounts of 
CNS S100B paradoxically promote apoptosis in mice prone 
to accelerated senescence (Grifﬁ  n et al 1998). Akhisaroglu 
et al (2003) compared the responses of young and old mice 
after administration of ﬂ  uoxetine 10 mg/kg daily for 2 weeks. 
The older mice had higher levels of S100B. Fluoxetine further 
increased that abnormal level of S100B. However, there were 
no cognitive or mood or behavioral descriptions of the older 
mice with or without ﬂ  uoxetine administration and therefore 
no clinical implications of the increased S100B. In addition, 
the authors did not mention effects of ﬂ  uoxetine on morbidity, 
mortality or brain pathology in the mice.
Overall, studies have shown that selected SSRIs could 
modify disease through effects on amyloid plaque formation 
or hippocampal neurogenesis. These beneﬁ  ts are not speciﬁ  c 
to SSRIs. Not all SSRIs are implicated in APP ectodomain Neuropsychiatric Disease and Treatment 2007:3(5) 633
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expression; the chemical structure of paroxetine appears 
more relevant than its intrinsic SSRI activity. Facilitation 
of neurogenesis is seen with other non-SSRI psychotropics. 
Preclinical testing for hippocampal neurogenesis in animal 
models with higher predictive validity may be warranted, 
but other antidepressants may be just as likely to provide 
this beneﬁ  t. At this time, the preclinical evidence supports 
SSRIs more speciﬁ  cally as a symptomatic treatment and less 
convincingly as a unique type of disease modiﬁ  er.
Clinical evidence
Our search revealed no clinical trials reporting disease 
modifying beneﬁ  ts of SSRIs, whether in CSF levels of AD 
biomarkers (eg, beta-amyloid, hyperphosporylated tau), 
neuropathological ﬁ  ndings, or retention or normalization of 
hippocampal volume or functional imaging characteristics.
Conclusion
Figure 1 illustrates the wide range of SSRI interactions with 
other modulators of the CNS, many of which probably impact 
the neurodegenerative process of AD. Preclinical studies extend 
promises that the beneﬁ  ts of SSRIs to patients with AD could 
depend on promotion of hippocampal-dependent learning by   
carbonic anhydrase activation or reduction of Aβ deposition in 
the brain. Although there have been clinical trials of SSRIs on 
AD, outcome measures have not examined the potential effects 
indicated by preclinical work. The clinical evidence reviewed 
gives more positive than negative evidence that SSRIs have 
beneﬁ  cial effects on cognitive function in AD patients, but these 
have not been shown to be independent of mood or behavioral 
improvement. Clinically, this may not be an important point to 
prove if mood and behavioral improvement add to the patient’s 
quality of life, but an important question remains unanswered: 
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would SSRIs be of beneﬁ  t for AD patients who are not actively 
manifesting mood or behavioral problems? The one negative 
study designed to address this question warrants replication in a 
larger sample with one of the SSRIs supported by the preclini-
cal evidence to have effects on AD pathology, eg, ﬂ  uoxetine, 
paroxetine, or citalopram.
Because SSRIs are already widely available to the AD 
population, an alternative to full development of preclini-
cal evidence would be the addition of appropriate outcome 
measures for showing disease modiﬁ  cation. Clinical trials 
may not be able to distill cognitive beneﬁ  t independent of 
mood or behavior effects unless they incorporate functional 
neuroimaging to identify brain activity enhanced differen-
tially in cognitive responders vs. non-responders. Ideally, 
studies should include neurochemical, neuroimaging, mood, 
behavioral, and cognitive outcome measures.
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